ArticleJournal of cancer research and clinical oncology2023

Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer.

Nanwei Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.